440
USE OF BACTERICIDAL RECIRCULATOR REFLASH 60 IN ADDITION TO
STANDARD THERAPY FOR SEVERE PNEUMONIA
Abdukarimova Mohinur Abdalim qizi
student of 424
th
group of pediatric faculty Samarkand State Medical
University Samarkand Uzbekistan
Isaeva Liliya Inbergovna
Scientific supervisor
free applicant of the department 1-Pediatrics and neonatology,
Samarkand State Medical University, Samarkand Uzbekistan
https://doi.org/10.5281/zenodo.10688873
Abstract.
Pathologies of the respiratory system in children occupy first place, both in terms
of overall morbidity and mortality. Research shows that among the etiological factors of
pneumonia, various bacterial and viral agents have been identified, the significance of which is
not fully understood, but these cases are characterized by mixed results, lack of complete data and
insufficient coverage in the literature.
Severe pneumonia is pneumonia characterized by severe respiratory failure (RF) and/or
signs of sepsis and multiple organ dysfunction. Today, the problem of severe pneumonia is
relevant, due to the high mortality of the disease, the presence of a wide range of poly- and multi-
resistant strains of microorganisms
Thus, at present, the study of severe pneumonia in children has not been sufficiently
studied, and the issue of using modern methods of preventing infection remains insufficiently
addressed. In this regard, issues related to establishing the degree of influence of modifiable and
non-modifiable factors on the development and course of severe pneumonia in children require
further study; it is necessary to search for new methods for predicting the course and outcome,
develop and implement new methods of treatment and prevention of the disease, which determined
the relevance of our research.
Key words:
children, approaches, severe pneumonia, bactericidal recirculator reflash-60.
ПРИМЕНЕНИЕ БАКТЕРИЦИДНОГО РЕЦИРКУЛЯТОРА REFLASH 60
ДОПОЛНИТЕЛЬНО К СТАНДАРТНОЙ ТЕРАПИИ ПРИ ТЯЖЕЛОЙ
ПНЕВМОНИИ
Аннотация.
Патологии органов дыхания у детей занимают первое место как по
общей заболеваемости, так и по смертности. Исследования показывают, что среди
этиологических факторов пневмонии выявлены различные бактериальные и вирусные
441
агенты, значение которых до конца не изучено, однако эти случаи характеризуются
неоднозначными результатами, отсутствием полных данных и недостаточным
освещением в литературе.
Тяжелая пневмония – это пневмония, характеризующаяся тяжелой дыхательной
недостаточностью (ТД) и/или признаками сепсиса и полиорганной дисфункции. На
сегодняшний день проблема тяжелых пневмоний актуальна в связи с высокой
летальностью заболевания, наличием широкого спектра поли- и полирезистентных
штаммов микроорганизмов.
Таким образом, в настоящее время изучение тяжелых пневмоний у детей
недостаточно изучено, а вопрос использования современных методов профилактики
инфекции остается недостаточно решенным. В связи с этим вопросы, связанные с
установлением степени влияния модифицируемых и немодифицируемых факторов на
развитие и течение тяжелой пневмонии у детей, требуют дальнейшего изучения;
необходим поиск новых методов прогнозирования течения и исхода, разработка и
внедрение новых методов лечения и профилактики заболевания, что и определило
актуальность наших исследований.
Ключевые слова:
дети, подходы, тяжелая пневмония, бактерицидный
рециркулятор Рефлеш-60.
Relevance.
Respiratory diseases in children are one of the important problems of pediatrics
and pediatric pulmonology. Despite the advances made in diagnosis and treatment, respiratory
diseases still occupy one of the first places among the diseases of children and adolescents. [1,2,7].
The growing trend of respiratory pathology in children and the possibility of a high risk of relapse
of severe pneumonia determine the relevance of studying the factors and mechanisms of the
formation of pneumonia in children. Currently, the relevance of works devoted to the significance
of markers that determine the course of the disease and the effectiveness of antibacterial therapy
remains. Data are provided on the prognostic capabilities of virological examination of sputum,
respiratory smear by polymerase chain reaction, determination of the degree of air pollution, study
of indicators of the blood coagulation system, determination of the level of inflammatory markers
in children, as the most informative laboratory criteria for diseases and the need for their timely
determination. Determining the level of indicators of the blood coagulation system allows you to
reduce the duration of ABT by 1.5-2 times, the length of hospital treatment, reduce the frequency
of adverse drug manifestations, be one of the indicators of a complicated outcome of the disease,
442
and help reduce the development of bacterial resistance in children [10]. Inflammation, which is
the main component of the pathogenetic component of the formation of clinical signs of respiratory
tract damage in atypical pneumonia, and the severity of the condition of patients with reduced
immunity in the acute period of the disease force us to look for new methods of treatment,
diagnosis and prevention [3,5,9]. Today, one of the methods of prevention and treatment is a
bactericidal recirculator - a device used to disinfect indoor air in the presence of people, purifying
the air from viruses, bacteria, microbes and allergens. In patients during whose treatment a
bactericidal recirculator was used, the div's protective properties against bacteria and viruses are
enhanced, the frequency of acute respiratory infections is reduced, their duration is shortened, and
the likelihood of complications of severe pneumonia is reduced. [4,6,8]. Children treated with
standard therapy in combination with the use of a bactericidal recirculator both in outpatient and
inpatient settings experienced accelerated clinical recovery, as well as faster disappearance of
symptoms compared to traditional therapy.
The purpose of the scientific work:
to study the effectiveness of using a bactericidal
recirculator apparatus in the treatment of severe pneumonia in children.
Materials and methods of research.
Depending on the prescribed therapy, 90 patients
aged from 12 months to 12 years, undergoing inpatient treatment in the children's departments of
the Samarkand branch of the Russian Research Center for Emergency Medical Care, were divided
into 2 groups. The main group of 60 children with severe pneumonia and the second group of 30
children with severe course of pneumonia. In both groups, anamnestic and follow-up data were
collected, examinations were carried out using generally accepted clinical, laboratory,
instrumental, and also special research methods. Patients of the first group were divided into two
subgroups. Group 1a of 30 children received standard therapy, a set of preventive measures, and
the bactericidal recirculator reflash 60 was used in addition to standard therapy; subgroup 1b
received only standard therapy.
Study results:
Indications for hospitalization in 48 (66.6%) patients were acute respiratory
failure, 52 (%) increased div temperature, 56 (%) cough, rhinorrhea in 46 (%) patients, sore
throat in 34 (%) broncho-obstructive syndrome in 48 (16.6%) patients, toxicosis in 12 (16.6%)
patients. All patients received appropriate antibiotics and symptomatic therapy.
Indicators of inflammatory markers and cytokines in patients with severe pneumonia
(M±m)
443
Indicators
Normal
indicators
Severe
course
of
pneumonia
Р
CRP (mg/l)
3,3±0,2
35,0±0,9
<0,001
PCT (ng/l)
0,16±0,01
1,23±0,03
<0,001
IL-4 pg/ml
4,8±0,3
15,4±0,4
<0,001
IL-6 pg/ml
16,3±0,7
46,8±3,1
<0,001
TNF-α pg/ml
24,5±0,8
57,8±1,5
<0,001
Note: P – reliability of differences between normative
An increase in the concentration of inflammatory markers and cytokines in patients
indicates a response of the childs div to an infectious agent, the degree of which most likely
depends on the specific etiological agent, the results of which will be presented in a comparative
analysis in children with severe pneumonia.
Analysis of changes in the blood coagulation system in patients with severe pneumonia
showed that the concentrations of the determined indicators in the blood were significantly higher
both in comparison with standard indicators and with the level of severe pneumonia.
In subgroup 1a, patients receiving standard therapy in combination with the use of the
bactericidal recirculator reflash 60 experienced rapid positive dynamics, a decrease in the addition
of a secondary infection, and a shortening of bed days. Improvement in general condition and
regression of clinical manifestations of the disease were recorded 2.2 days earlier in patients of
group Ia than in group Ib.
The discussion of the results. According to the results of examination and treatment of
severe pneumonia in children who took standard therapy and our proposed complex of treatment
and preventive measures using the bactericidal recirculator reflash 60, in addition to standard
therapy, was accompanied by rapid positive dynamics, signs of intoxication were relieved by an
average of 3.8 ± 0 .3 days, cough disappeared for 5.4 ± 0.4 days, percussion changes in the lungs
normalized for 6.6 ± 0.3, auscultatory changes for 6.7 ± 0.4 days. No adverse reactions were
observed when using the bactericidal recirculator.
Conclusions.
Thus, a bactericidal recirculator, in addition to standard therapy, helps reduce
the incidence of severe pneumonia, reduce the risk of secondary infection, reduces the likelihood
of aggravating the course of severe pneumonia, and also increases the divs resistance to
infections of the respiratory system. Ease of use, high efficiency and absence of significant side
effects allow us to recommend this device for wide use in pediatrics.
444
REFERENCES
1.
Diagnostic algorithms and protocols for providing medical care for pneumonia:
methodological recommendations for doctors / Demko I.V., Chubarova S.V., Gordeeva
N.V., Zeleny S.V. and etc.; Ministry of Health of the Krasnoyarsk Territory, State
Budgetary Educational Institution of Higher Professional Education of Krasnoyarsk State
Medical University named after. prof. V.F. Voino-Yasenetsky Ministry of Health of
Russia. M., 2015. 75 p.
2.
Gorbich, O. A. Severe pneumonia is a significant problem in childhood / O. A. Gorbich //
Medical Journal. - 2016. - No. 3. - P. 57-61.
3.
Ibragimova, M. F. (2022). Use of the drug pectolvanc in the treatment of atypical
pneumonia in children. Editor-in-Chief Zh A Rizaev, 35.
4.
Zaplatnikov A.L., Girina A.A., Maykova I.D., Karoid N.V., Lepiseva I.V., Svintsitskaya
V.I., Logacheva T.S. Clinic, diagnosis and treatment of respiratory M.pneumoniae
infection in children. Medical advice. 2019; (17):91-98.
5.
Farrukh S. ORGANIZATION OF DIGITALIZED MEDICINE AND HEALTH
ACADEMY AND ITS SIGNIFICANCE IN MEDICINE //Science and innovation. – 2023.
– Т. 2. – №. Special Issue 8. – С. 493-499.
6.
Ibragimova, M. F. (2022).
Diagnostic criteria for pneumonia of atypical etiology in
children
.
British Medical Journal
,
2
(5).
7.
Fedorovna, I. M. (2022).
The influence of risk factors on the development of atypical
pneumonia in young children
.
Asian journal of pharmaceutical and biological
research
,
11
(2).
8.
Mamedovich, S. N., & Fedorovna, I. M. (2022).
Efficacy of vilprafen and resistol in
community-acquired pneumonia with atypical etiology in children.
Thematics Journal of
Applied Sciences
,
6
(1).
9.
Rustamov, M., Ibragimova, M., & Xusainova, S. (2023). Особенности клинико-
диагностических критерий микоплазменной пневмонии у детей.
International
Journal of Scientific Pediatrics
, (2), 05-08.
10.
Shavazi, N., & Ibragimova, M. (2023). Применение препарата полиоксидоний при
лечении обструктивного бронхита у детей.
International Journal of Scientific
Pediatrics
, (1), 26-28.
445
11.
Waites K. B. et al. Mycoplasma pneumoniae from the respiratory tract and beyond
//Clinical microbiology reviews. – 2017. – Т. 30. – №. 3. – С. 747-809.
https://pubmed.ncbi.nlm.nih.gov/28539503/
